TP53 and cancer: As suggested by recent studies demonstrating the failure of anti-MdmX strategy in tumors expressing hypomorphic p53 mutant,46 our data indicate that cancer treatments centered on MdmX inhibition should be employed only in cases where tumor retains functional p53.